P2-144: Serum levels of VEGF C, VEGF D and sVEGFR2 in patients with lung cancer during chemotherapy  by Naumnik, Wojciech et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS548
lyze the levels of sFas, sFasL and OPG in lung cancer in relation to the 
histological type of the tumor, clinical stage, response to therapy. The 
study included 48 patients (NSCLC- Non Small Cell Lung Cancer) and 
15 healthy subjects as controls. Peripheral venous blood samples were 
collected before and after chemotherapy. sFas, sFasL and OPG serum 
levels were measured with a Elisa kits (R&D; Bender MS.).
The mean serum values of OPG, sFas and sFasL were signiﬁ-
cantly higher in cancer patients than in controls (OPG: 4,2±1,2 vs 
3,16±0,8pmol/l; sFas: 1253,0±389 vs 981,7±272 pg/ml; sFasL: 
352,3±47 vs 556,7±84 pg/ml). There was no difference of OPG in 
relation to response to therapy. sFas mean levels observed at the end of 
chemotherapy were higher in responders patients than in the progressed 
ones (p=0,008). The metastatic patients had higher levels of OPG and 
sFas than those without metastases. The mean serum value of sFas 
were signiﬁcantly higher in no weight loss patients (p=0,03). In our 
opinion, OPG, sFas and sFasL levels may be a helpful during therapy 
of lung cancer, but their clinical signiﬁcance needs further investiga-
tions.
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Neoangiogenesis plays a vital role in the growth of a cancerous tumor 
and the development of metastasis. Vascular endothelial growth fac-
tor is a main agent triggering neoangiogenesis. The family of VEGF 
consists of many growth factors, e.g., VEGF A, VEGF B, VEGF C, 
VEGF D. VEGF C and VEGF D are relatively less known. The recep-
tor of VEGF R2 is a main receptor taking part in neoangiogenesis. The 
present study was carried out to analyze the levels of VEGF C, VEGF 
D and sVEGFR2 in lung cancer in relation to the histological type of 
the tumor, clinical stage, response to therapy. The study included 80 
patients (36 SCLC, 44 NSCLC) and 20 healthy subjects as controls. 
Peripheral venous blood samples were collected before and after 
chemotherapy. VEGF C, VEGF D and sVEGFR2 serum levels were 
measured with a sandwich enzyme immunoassay using commercial kits 
(R&D System). Serum levels of VEGF C, VEGF D were signiﬁcantly 
higher in both NSCLC and SCLC groups in comparison with controls 
(VEGF C: NSCLC: 7,8±2,4 vs 4,56±1,8 ng/ml; SCLC: 7,96±2,7 vs 
4,56±1,8; VEGF D: NSCLC: 1,02±0,5 vs 0,57±0,1 ng/ml; SCLC: 
1,04±0,8 vs 0,57±0,1; sVEGFR2: NSCLC: 12,63±3,1 vs 15,64±5,2; 
SCLC: 13,42±3,8 vs 15,64±5,2 ng/ml). VEGF C concentration de-
creased after chemotherapy, whereas VEGF D concentration was at the 
same level. No correlation was found between VEGF C and VEGF D 
concentrations and the effect of treatment. Patients with lung cancer 
and progression after chemotherapy (PD) had the higher concentration 
of sVEGFR2 than patients with partial remission (PR) (13,19±2,7 vs 
11,74±2,7 ng/ml). The levels of sVEGF R2 were lower before and after 
treatment than in controls (p<0,05). No relation was found between 
VEGF C, VEGF D and sVEGF R2 concentrations and the histological 
type and staging of lung cancer. 
Summing up, serum concentrations of VEGF C, VEGF D were higher 
in patients with lung cancer both before and after chemotherapy than 
in healthy people, whereas sVEGF R2 concentration is lower than in 
healthy people. An increase in concentration of sVEGF R2 during che-
motherapy may suggest progression of the disease. However, it requires 
further examinations. 
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Background: Metastatic spread constitutes the primary source of mor-
bidity and mortality of Non Small Cell Lung Cancer (NSCLC). Migra-
tion of cells is an important step in the metastatic process. A successful 
anti-migration strategy would be applicable in both the adjuvant setting 
(prevent primary metastasis) and the metastatic setting (inhibit further 
metastatic disease developing). One possible anti-migration approach is 
inhibition of the CXCR4/ SDF-1 axis.
CXCR4 is a well described G protein coupled chemokine receptor that 
has a role in cellular movement. CXCR4 and its ligand, stromal cell 
derived factor-1 (SDF-1), play a critical role in leukocyte trafﬁcking 
and homing of hematopoietic stem cells. Binding of CXCR4 by SDF-
1 results in the activation of many downstream pathways including 
mitogen-activated protein kinase, phosphatidylinositol 3-kinase, and 
calcium mobilization. SDF-1 is constitutively released by stromal cells 
from bone marrow, lung and liver which are common sites of tumor 
metastasis. In turn, CXCR4 is highly expressed on NSCLC tumor cells. 
However, the role of CXCR4 in the migration of NSCLC cells has not 
been extensively explored. We investigated the effect of modulation of 
the CXCR4/SDF-1 axis would have on lung cancer cell migration.
Methodology: Two human NSCLC cell lines (H460 and H1299) were 
used. CXCR4 expression was assessed by western blotting and ﬂow cy-
tometry. Migration patterns were investigated using a 48-well Boyden 
chamber. Cells added to the upper wells were separated from the lower 
wells by a coated polycarbonate ﬁlter. Chemoattractants (increasing 
concentrations of fetal calf serum (FCS), SDF-1) and/or inhibitors were 
added to the lower wells. After incubation, non-migrating cells on the 
top side of the ﬁlter were wiped off. The migrating cells, adherent to 
the underside of the ﬁlter, were stained with hematoxylin and counted 
microscopically at 20x magniﬁcation. 
Results: Both NSCLC cell lines express CXCR4 on their surface. 
Filters containing 8um pores impeded cell migration compared to those 
with 12um sized pores. Both cell lines migrated across the membrane 
in response to increasing concentrations of FCS, with 20% being the 
optimal concentration. Stimulation of CXCR4 by an SDF-1 agonist ap-
pears to stimulate migration of both NSCLC cell lines, while inhibition 
of this axis by anti CXCR-4 antibodies reduced the proportion of cell 
migration across the Boyden Chamber membrane by more than 60%. 
This inhibition persisted even in the presence of 20% FCS or SDF-1. 
Conclusions: Inhibition of the CXCR4/SDF-1 axis appears to inhibit 
the migration of these NSCLC cells in vitro. The CXCR4 axis may 
play a role in inﬂuencing the migrational behavior of NSCLC cells 
in vivo. Additional experiments to assess the role of small molecular 
inhibitors of CXCR4 are currently underway. These results suggest that 
use of CXCR4 inhibition strategies may be a useful therapeutic tool to 
